Seemal R. Desai, MD

Articles by Seemal R. Desai, MD

How to Educate Dermatology Patients on Colorism Issues, With Seemal Desai, MD, and Pearl Grimes, MD

ByPearl E. Grimes, MD,Seemal R. Desai, MD

May 13th 2026

This segment of a recent Skin of Color Savvy podcast highlights the experts' views on education related to colorism and skin pigment-related concerns.

Discussing Colorism and Pigmentary Disorders, With Seemal Desai, MD, and Pearl Grimes, MD

BySeemal R. Desai, MD,Pearl E. Grimes, MD

May 12th 2026

Seemal R. Desai, MD, and Pearl E. Grimes, MD, discuss the complexities of colorism and its impact on pigmentary disorders.

Skin of Color Savvy: Tackling Colorism in Dermatology, With Seemal Desai, MD, and Pearl Grimes, MD

BySeemal R. Desai, MD,Pearl E. Grimes, MD

March 24th 2026

In this episode of the Skin of Color Savvy podcast, 2 leaders in dermatology discuss the complexities of colorism and its impact on pigmentary disorders.

Advice for Dermatologists in Treating Psoriasis in Patients With Skin of Color

ByLinda Stein Gold, MD,Mona Shahriari, MD, FAAD,Seemal R. Desai, MD

April 4th 2024

Dr Linda Stein Gold, Dr Mona Shahriari and Dr Seemal Desai share advice for improving psoriasis care for patients with skin of color.

Data With Biologics in Patients With Skin of Color

ByLinda Stein Gold, MD,Mona Shahriari, MD, FAAD,Seemal R. Desai, MD

April 4th 2024

Dr Linda Stein Gold, Dr Mona Shahriari and Dr Seemal Desai share how they utilize biologics data from skin of color cohorts in their practice.

Early Use of Systemic Treatments in Patients With Skin of Color

ByLinda Stein Gold, MD,Mona Shahriari, MD, FAAD,Seemal R. Desai, MD

April 4th 2024

Drs Stein Gold and Desai share their thoughts on the early use of psoriasis systemic treatments in patients with skin of color.

Results of VISIBLE Trial in Patients With Skin of Color

ByLinda Stein Gold, MD,Mona Shahriari, MD, FAAD,Seemal R. Desai, MD

March 28th 2024

Dermatology experts highlight VISIBLE trial results when using guselkumab in patients with skin of color.

Guselkumab in Patients With Skin of Color: VISIBLE Trial Design

ByLinda Stein Gold, MD,Mona Shahriari, MD, FAAD,Seemal R. Desai, MD

March 28th 2024

Dr Linda Stein Gold, Dr Mona Shahriari and Dr Seemal Desai discuss VISIBLE trial, a randomized clinical trial specifically designed to examine treatment outcomes with guselkumab in patients with skin of color.

Traditional Systemic Therapy for Psoriasis for Patients With Skin of Color

ByLinda Stein Gold, MD,Mona Shahriari, MD, FAAD,Seemal R. Desai, MD

March 21st 2024

Drs Desai, Shahriari, and Stein Gold examine use and place of traditional systemic treatments in psoriasis.

Topical Treatments for Psoriasis for Patients With Skin of Color

ByLinda Stein Gold, MD,Mona Shahriari, MD, FAAD,Seemal R. Desai, MD

March 21st 2024

Dr Stein Gold and Dr Shahriari review steroidal and non-steroidal topical treatments that are available for use in psoriasis.

Post-Inflammatory Dyspigmentation in Patients With Skin of Color

ByLinda Stein Gold, MD,Mona Shahriari, MD, FAAD,Seemal R. Desai, MD

March 14th 2024

Dr Linda Stein Gold and Dr Mona Shahriari discuss post-inflammatory dyspigmentation in patients with skin of color and its impact on patient’s quality of life.

Communicating With Patients With Psoriasis With Skin of Color

ByLinda Stein Gold, MD,Mona Shahriari, MD, FAAD,Seemal R. Desai, MD

March 14th 2024

2 expert dermatologists provide tips for communicating, in a culturally sensitive manner, with patients with skin of color.

Social and Cultural Stigma of Psoriasis in Patients With Skin of Color

ByLinda Stein Gold, MD,Mona Shahriari, MD, FAAD,Seemal R. Desai, MD

March 7th 2024

Drs Stein Gold, Shahriari and Desai highlight social and cultural stigma of psoriasis in patients with skin of color and its impact on patient’s quality of life.

Presentation of and Challenges in Treatment of Psoriasis in Patients With Skin of Color

ByLinda Stein Gold, MD,Mona Shahriari, MD, FAAD,Seemal R. Desai, MD

March 7th 2024

Expert dermatologists review the presentation of psoriasis in patients with skin of color and the challenges physicians face in diagnosing psoriasis in this patient population.

Advances in oHCM Therapy

ByAnjali Owens, MD,Andrew Wang, MD,James Januzzi, MD,Michelle M. Kittleson, MD, PhD,Seemal R. Desai, MD

September 14th 2023

Milind Desai, MD, MBA, comments on the broadening knowledge in the oHCM space, leading to the development of new therapies.

Septal Reduction Therapies in oHCM

ByAnjali Owens, MD,Andrew Wang, MD,James Januzzi, MD,Michelle M. Kittleson, MD, PhD,Seemal R. Desai, MD

September 7th 2023

Expert cardiologists share approaches to the challenges that come with septal reduction therapy, as well as access to oHCM treatment.

Key Takeaways on Vitiligo Management

BySeemal R. Desai, MD,Heather Woolery-Lloyd, MD,Brittany G. Craiglow, MD,Nada Elbuluk, MD, MSc, FAAD,Ted Lain, MD

May 24th 2023

Expert dermatologists share final thoughts on treatment of vitiligo and topical ruxolitinib.

Promoting Access to New Therapies in Vitiligo

BySeemal R. Desai, MD,Heather Woolery-Lloyd, MD,Brittany G. Craiglow, MD,Nada Elbuluk, MD, MSc, FAAD,Ted Lain, MD

May 24th 2023

Experts in dermatology comment on the need to promote access to emerging treatments in vitiligo.

Managing Vitiligo Patient Expectations

BySeemal R. Desai, MD,Heather Woolery-Lloyd, MD,Brittany G. Craiglow, MD,Nada Elbuluk, MD, MSc, FAAD,Ted Lain, MD

May 24th 2023

Heather Woolery-Lloyd, MD, and Nada Elbuluk, MD, share approaches to patient education and managing patient expectations when repigmenting the skin in vitiligo.

Disease Burden for Patients With Vitiligo

BySeemal R. Desai, MD,Heather Woolery-Lloyd, MD,Brittany G. Craiglow, MD,Nada Elbuluk, MD, MSc, FAAD,Ted Lain, MD

May 17th 2023

Expert dermatologists discuss the impact of vitiligo and vitiligo treatment on quality of life.

Treatment Response to Conventional vs Emerging Therapies in Vitiligo

BySeemal R. Desai, MD,Heather Woolery-Lloyd, MD,Brittany G. Craiglow, MD,Nada Elbuluk, MD, MSc, FAAD,Ted Lain, MD

May 17th 2023

Nada Elbuluk, MD, and Ted Lain, MD, compare response to conventional treatment options vs emerging therapies, such as ruxolitinib, in the treatment of vitiligo.

Treatment Approaches to Ruxolitinib in Vitiligo

BySeemal R. Desai, MD,Heather Woolery-Lloyd, MD,Brittany G. Craiglow, MD,Nada Elbuluk, MD, MSc, FAAD,Ted Lain, MD

May 10th 2023

Experts in dermatology share their impressions of ruxolitinib and approaches to vitiligo treatment in clinical practice.

Adverse Events of Ruxolitinib in Vitiligo Trials

BySeemal R. Desai, MD,Heather Woolery-Lloyd, MD,Brittany G. Craiglow, MD,Nada Elbuluk, MD, MSc, FAAD,Ted Lain, MD

May 10th 2023

Heather Woolery-Lloyd, MD, discusses the adverse event profile of topical ruxolitinib for treatment of vitiligo, highlighting the well-tolerated nature of the drug.

Impact of UV Light Exposure on Vitiligo

BySeemal R. Desai, MD,Heather Woolery-Lloyd, MD,Brittany G. Craiglow, MD,Nada Elbuluk, MD, MSc, FAAD,Ted Lain, MD

May 3rd 2023

Expert dermatologists comment on the impact of UV light exposure on areas of the skin with vitiligo and their recommendations for sunscreen use.

Use of Ruxolitinib for Treatment of Vitiligo

BySeemal R. Desai, MD,Heather Woolery-Lloyd, MD,Brittany G. Craiglow, MD,Nada Elbuluk, MD, MSc, FAAD,Ted Lain, MD

May 3rd 2023

Experts in dermatology review the mechanism of action and clinical trials of topical ruxolitinib for repigmenting the skin in vitiligo.

Measuring Vitiligo Treatment Response

BySeemal R. Desai, MD,Heather Woolery-Lloyd, MD,Brittany G. Craiglow, MD,Nada Elbuluk, MD, MSc, FAAD,Ted Lain, MD

April 26th 2023

Brittany Craiglow, MD, discusses the lengthy nature of vitiligo treatment response and how to approach communicating with patients who want to see change quickly.